
Evolocumab for Heart Risk Before a First Heart Attack or Stroke
PCSK9 inhibitors represent a major advance in cholesterol management. The VESALIUS-CV trial shows that evolocumab reduces first cardiovascular events in patients with atherosclerosis or diabetes, even without a prior heart attack or stroke. These findings expand prevention strategies beyond traditional secondary prevention and support earlier, more personalized lipid lowering approaches.
Published
